29958537694: Difference between revisions
From Verified Handles
company
29958537694
29958537694
(Created by auto-bot V1) |
(AB-V1) |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:UCB}} | {{DISPLAYTITLE:UCB}} | ||
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small> | UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.<small> from [https://en.wikipedia.org/wiki/UCB_(company) Wikipedia]</small> | ||
{{SF| | {{SF| | ||
{{Twt|ucb_news}} | {{Twt|ucb_news}} | ||
| Line 8: | Line 7: | ||
}} | }} | ||
{{IDF| | {{IDF| | ||
{{Isni|000000012154737X}} | {{Isni|000000012154737X}} | ||
}} | }} | ||
Latest revision as of 17:18, 27 February 2022
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. from Wikipedia
| Icon | Service | Username | |
|---|---|---|---|
 |
@ucb_news |  | |
|
@UCBUSA | | |
 |
Website | ucb.com | |
Additional identifiers
These are provided for reference and have been verified to be accurate.
| Icon | Database | Identifier | |
|---|---|---|---|
 |
ISNI | 000000012154737X | |